Halozyme offers a wide economic moat, 42% year-over-year revenue growth, and a forward P/E of 7.2x with a PEG of 0.23 — a combination suggesting the market has not fully priced its growth trajectory; the stock has reached the analyst consensus target with only 2.4% remaining upside from current levels, making the setup compelling at a pullback entry but stretched at spot.
Thesis pillars
- Wide Moat Quality Franchise→Stable
- High Growth Cheap Valuation→Stable
- Earnings Execution Mixed Signal→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 17, 2026· older than 90 days
Halozyme Therapeutics, Inc. (HALO) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $128.62, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away).
Halozyme Therapeutics licenses its ENHANZE drug delivery technology to pharma partners including Roche, Janssen, AbbVie, and Pfizer to convert IV biologics to subcutaneous delivery. Revenue comes from upfront licensing fees, milestone payments, bulk rHuPH20 enzyme sales, and... Read more
Hold if already holding. Not a fresh buy at $128.62, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away). Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $128.62 vs the analyst target $94.73: -26.3% upside; No upside left. Score 6.3/10, moderate confidence.
Passes 5/9 gates (positive momentum, clean insider activity, news boost analyst 0.40, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 1d<=7d. Suitability: speculative.
About Halozyme Therapeutics, Inc.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics earns royalties on 10 commercially approved drugs co-formulated with ENHANZE, including five from Roche (among them TECENTRIQ HYBREZA and OCREVUS ZUNOVO, both FDA-approved in September 2024) and two from Janssen (DARZALEX FASPRO and RYBREVANT FASPRO, the latter FDA-approved in December 2025), plus products from Takeda, argenx, and BMS across 13 active collaborations. The company also markets proprietary products Hylenex and XYOSTED in the U.S. market.
Halozyme's revenue model rests on four streams: upfront licensing fees when a new collaboration begins; event-based and sales milestone payments tied to development, regulatory, and commercial targets; bulk rHuPH20 enzyme supply sales to manufacturing partners; and running royalties on approved product revenues. Partners obtain worldwide licenses to combine rHuPH20 with their own proprietary biologics for specific molecular targets; the current roster includes Roche, Janssen, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, and ViiV Healthcare. Distribution is entirely through pharma partners, who conduct clinical development, regulatory submissions, and commercial launches globally. Halozyme's own commercial portfolio—Hylenex (the number-one prescribed branded hyaluronidase in the U.S.) and XYOSTED (the only FDA-approved once-weekly subcutaneous testosterone enanthate)—generates direct product revenue alongside the royalty streams. The company also expanded into Hypercon and Surf Bio drug delivery technologies through the acquisition of Elektrofi, subsequently renamed Halozyme Hypercon.
Show full overview
The foundation of Halozyme's commercial model is its rHuPH20 enzyme, manufactured by third-party vendors. The 10-K identifies disruptions in bulk rHuPH20 supply as a material risk that could delay or suspend development and commercialization across multiple collaborations simultaneously—since the enzyme underpins all 13 active ENHANZE programs, a supply failure could affect all partner relationships at once rather than isolating to a single product. Separately, certain drugs co-formulated with ENHANZE have received regulatory exclusivity extensions, stretching patent life beyond the expiry of the original IV formulation and adding intellectual property durability to the royalty streams.
See also: Healthcare · Biotechnology
From Halozyme Therapeutics, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Oct 28, 2026Recent Developments — Halozyme Therapeutics, Inc.
Latest news
- NEWS What Did Halozyme Stock Investors Miss Before The Run? - Yahoo Finance — Yahoo Finance Oct 28, 2026 negative
- NEWS What Did Halozyme Stock Investors Miss Before The Run? - Trefis — Trefis Oct 28, 2026 negative
- NEWS Halozyme’s Strong Earnings Growth Sends Shares Higher - FXEmpire — FXEmpire Oct 21, 2026 positive
- NEWS Halozyme Therapeutics Adds James Daly to Board - TipRanks — TipRanks Sep 30, 2026 neutral
- NEWS Halozyme Therapeutics Adds James Daly to Board - tipranks.com — tipranks.com Sep 30, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-04T11:34:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-30Item 5.02MEDIUMDarren Snellgrove appointed as permanent CFO effective June 8, 2026, succeeding Interim CFO David Ramsay, who will transition to an advisory role. Snellgrove most recently served as VP Investor Relations at Johnson & Johnson and prior to that as CFO of J&J's Pharmaceutical sector from August 2021 to May 2025.SEC filing →
- 2026-03-12Item 5.02MEDIUMDavid Ramsay appointed as Interim CFO effective March 23, 2026. Previously served as company CFO from 2003 to 2009 and from 2013 to 2015. No reason for the prior CFO's departure cited; no permanent replacement named at time of filing.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 ceiling hits
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $128.62, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away). Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $128.62 vs the analyst target $94.73: -26.3% upside; No upside left. Analyst target $94.73 reached (−26.3%), stop $108.28 (−18.8%), A.R:R -1.8:1. Score 6.3/10, moderate confidence.
Analyst target $94.73 reached (−26.3% from $128.62); no take-profit level is published. Analyst target $94.73 reached (−26.3%), stop $108.28 (−18.8%), A.R:R -1.8:1. Stop-loss: $108.28.
Analyst target reached - limited upside remaining; Near 52-week high (4.0% away); Leverage penalty (D/E 15.2): -1.5.
Halozyme Therapeutics, Inc. trades at a P/E of 37.6 (forward 12.0). TrendMatrix value score: 5.7/10. Verdict: Hold.
16 analysts rate HALO, with a consensus score of 4.0/5. 9 analysts publish price targets averaging $109.
What does Halozyme Therapeutics, Inc. do?Halozyme Therapeutics licenses its ENHANZE drug delivery technology to pharma partners including Roche, Janssen,...
Halozyme Therapeutics licenses its ENHANZE drug delivery technology to pharma partners including Roche, Janssen, AbbVie, and Pfizer to convert IV biologics to subcutaneous delivery. Revenue comes from upfront licensing fees, milestone payments, bulk rHuPH20 enzyme sales, and royalties across 10 approved partner products in 13 active collaborations.